Trunome Lung care
Trunome Lung Care test utilizes cutting-edge technology to detect the risk of transplant rejection through a simple blood sample. Early identification of rejection can aid in preventing the loss of a transplanted lung, and help doctors plan the best treatment to protect the donated organ.
Trunome’s Lung Care test offers a non-invasive way to assess the risk of transplant rejection by analyzing a simple blood sample. Early detection of transplant rejection is crucial as it can prevent transplant failure, improve patient outcomes, and avoid the need for additional transplants. Without effective tests and treatment, many transplanted organs, particularly lungs, can fail soon after the transplantation. Early detection and intervention can help improve patient life and reduce the need to go through the long waitlist process again.
Trunome Lung Care test offers a crucial tool in ensuring the long-term success of lung transplants by providing regular, non-invasive monitoring through simple blood tests. The blood test helps detect the presence of antibodies or other markers that indicate rejection or injury, healthcare providers can take early action to protect the transplanted lung and improve patient outcomes.
The benefits of Trunome’s test, such as its ease of use and ability to facilitate repeated sampling for longitudinal analysis, make it essential in safeguarding the patient’s health and improving the overall quality of their life after transplantation.
Trunome is a non-invasive method, with a simple blood draw from the post-transplant patient. The collected blood is then analyzed to measure the amount of donor DNA from the transplanted kidney in the patient’s blood.
This measurement can help assess all types of organ rejection more precisely than standard assessment tools that are currently available.
